Reading RNAC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNAC free→Reading RNAC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNAC free→QuarterlyIQ Insights · RNAC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company. In connection therewith, the Company expects to enter into a separation agreement and release (the “Separation Agreement”) with Dr. Miljkovic on or about May 31, 2026 (the “Execution Date”), pursuant to which Dr. Miljkovic’…
The issuance of any Conversion Shares underlying the outstanding principal amount of the Term Loans will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D thereunder.
Entry into a Material Definitive Agreement. Loan and Security Agreement On May 22, 2026, Cartesian Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, Cartesian Bio, LLC, as borrowers (“Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with certain financial institutions party thereto as lenders (the “Lenders”), K2 HealthVentures LLC, as administrative agent (in such capacity, the “Administrative Agent”) and Ankura Trust Company, LLC, as collateral…
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities. Prior to his resignation, Dr. Kalayoglu served as Chairman of the Board’s Scien…
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 16, 2025, the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) appointed Adrian Bot, M.D., Ph.D. as a Class II director. Dr. Bot has been appointed to serve until the Company’s annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or his earlier death, dis…
Other Events On November 13, 2025, the Company announced initial data from its ongoing Phase 2 trial of Descartes-08 in participants with SLE. The Phase 2 open-label trial was designed to evaluate outpatient administration of Descartes-08 without preconditioning chemotherapy or integrating vectors for the treatment of participants with moderate or severe SLE refractory to immunosuppressant therapy. The primary outcome measure assesses safety and tolerability, with secondary outcome measures a…
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with her recent appointment as Executive Chair of another publicly-traded company and the additional responsibilities and time commitment related thereto, on October 29, 2025, Carrie S. Cox, a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of her resignation from th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15, 2025, Cartesian Therapeutics, Inc. (the “Company”) eliminated the position of Chief Scientific Officer and delivered a notice of termination of employment without cause to Christopher Jewell, Ph.D., who currently serves as the Company’s Chief Scientific Officer, each effective as of November 14, 2025. On October 20, 2025, the Company…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2025, the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) appointed June Seymour as the Company’s Chief Accounting Officer, effective upon the commencement of Ms. Seymour’s full-time employment with the Company on October 27, 2025 (the “Effective Date”). Ms. Seymour, age 48, brings over two decades of…
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 29, 2025, Cartesian Therapeutics, Inc. (the “Company”) entered into a (i) consulting agreement (the “Consulting Agreement”) and (ii) separation agreement and release (the “Separation Agreement,” and together with the Consulting Agreement, the “Agreements”), each with the Company’s Chief Technology Officer, Metin Kurtoglu. Dr. Kurtoglu’s em…
Other Information. On April 8, 2025, the Company announced 12-month efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized MG. Participants dosed with a single six-week course of treatment of Descartes-08 were observed to continue to experience a sustained benefit in symptoms of MG at the 12-month assessment. The primary efficacy dataset for the follow-up portion of the trial consisted of a modified intent-to-treat (“mITT”) population of all subjects…
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.